Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29105
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam M. | en |
dc.contributor.author | Prenen H. | en |
dc.contributor.author | Body A. | en |
dc.contributor.author | Segelov E. | en |
dc.contributor.author | Lum C. | en |
dc.date.accessioned | 2021-05-14T09:49:20Z | en |
dc.date.available | 2021-05-14T09:49:20Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200910 | en |
dc.date.issued | 2020-09-10 | en |
dc.identifier.citation | Expert Review of Gastroenterology and Hepatology. 14 (8) (pp 665-680), 2020. Date of Publication: 02 Aug 2020. | en |
dc.identifier.issn | 1747-4124 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29105 | en |
dc.description.abstract | Introduction: Anal cancer is a rare malignancy with increasing incidence, notably in women. This disease is highly associated with HPV infection and its incidence and mortality are currently rising. Most patients present with localized disease which has a high survival after definitive treatment with chemoradiation. For patients who develop metastatic disease or present with this de novo, survival is poor. Areas covered: This review provides a summary of current literature on anal cancer. With a focus on women, this includes current epidemiological trends, role of HPV, and the current and future treatment landscape, including HPV vaccination and immunotherapy. Screening currently focusses on HIV-positive men, missing most female cases. In curative disease, trials are investigating treatment de-intensification in good prognostic groups. Immunotherapy is showing early promise in the advanced disease setting. Expert opinion: Similar to cervical cancer, anal cancer is strongly associated with HPV, and therefore, broader implementation of screening programs may reduce its incidence. HPV vaccination is expected to reduce the development of (pre)malignant anal lesions. The emergence of biomarkers will assist patient treatment selection, allowing optimal balance of treatment efficacy and morbidity. It is hoped that new treatment approaches, including immunotherapy, will improve outcomes. International collaboration is needed.Copyright © 2020 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Taylor and Francis Ltd | en |
dc.relation.ispartof | Expert Review of Gastroenterology and Hepatology | en |
dc.subject | cross infection | en |
dc.subject | digital rectal examination | en |
dc.subject | epidemiological data | en |
dc.subject | hormone action | en |
dc.subject | immunocompromised patient | en |
dc.subject | infection prevention | en |
dc.subject | intensity modulated radiation therapy | en |
dc.subject | mixed infection | en |
dc.subject | nonhuman | en |
dc.subject | papillomavirus infection | en |
dc.subject | pathophysiology | en |
dc.subject | positron emission tomography-computed tomography | en |
dc.subject | prevalence | en |
dc.subject | radiation injury | en |
dc.subject | review | en |
dc.subject | risk assessment | en |
dc.subject | risk factor | en |
dc.subject | salvage therapy | en |
dc.subject | sexual behavior | en |
dc.subject | sexually transmitted disease | en |
dc.subject | smoking habit | en |
dc.subject | treatment duration | en |
dc.subject | treatment response | en |
dc.subject | trend study | en |
dc.subject | uterine cervix cancer | en |
dc.subject | viral clearance | en |
dc.subject | virus strain | en |
dc.subject | atezolizumab/cb [Drug Combination] | en |
dc.subject | atezolizumab/dt [Drug Therapy] | en |
dc.subject | avelumab/cb [Drug Combination] | en |
dc.subject | avelumab/cm [Drug Comparison] | en |
dc.subject | capecitabine/ct [Clinical Trial] | en |
dc.subject | capecitabine/dt [Drug Therapy] | en |
dc.subject | carboplatin/ct [Clinical Trial] | en |
dc.subject | carboplatin/cb [Drug Combination] | en |
dc.subject | carboplatin/dt [Drug Therapy] | en |
dc.subject | cetuximab/ct [Clinical Trial] | en |
dc.subject | cetuximab/cb [Drug Combination] | en |
dc.subject | cetuximab/cm [Drug Comparison] | en |
dc.subject | cetuximab/dt [Drug Therapy] | en |
dc.subject | circulating tumor DNA/ec [Endogenous Compound] | en |
dc.subject | cisplatin/ct [Clinical Trial] | en |
dc.subject | cisplatin/cb [Drug Combination] | en |
dc.subject | cisplatin/cm [Drug Comparison] | en |
dc.subject | cisplatin/dt [Drug Therapy] | en |
dc.subject | docetaxel/cb [Drug Combination] | en |
dc.subject | docetaxel/cm [Drug Comparison] | en |
dc.subject | docetaxel/dt [Drug Therapy] | en |
dc.subject | durvalumab/dt [Drug Therapy] | en |
dc.subject | estrogen | en |
dc.subject | fluorouracil/ae [Adverse Drug Reaction] | en |
dc.subject | fluorouracil/ct [Clinical Trial] | en |
dc.subject | fluorouracil/cb [Drug Combination] | en |
dc.subject | fluorouracil/cm [Drug Comparison] | en |
dc.subject | fluorouracil/dt [Drug Therapy] | en |
dc.subject | ipilimumab/cb [Drug Combination] | en |
dc.subject | ipilimumab/cm [Drug Comparison] | en |
dc.subject | ipilimumab/dt [Drug Therapy] | en |
dc.subject | mitomycin/ae [Adverse Drug Reaction] | en |
dc.subject | mitomycin/cb [Drug Combination] | en |
dc.subject | mitomycin/dt [Drug Therapy] | en |
dc.subject | nivolumab/ct [Clinical Trial] | en |
dc.subject | nivolumab/cb [Drug Combination] | en |
dc.subject | nivolumab/cm [Drug Comparison] | en |
dc.subject | nivolumab/dt [Drug Therapy] | en |
dc.subject | pembrolizumab/ct [Clinical Trial] | en |
dc.subject | pembrolizumab/dt [Drug Therapy] | en |
dc.subject | Wart virus vaccine | en |
dc.subject | human | en |
dc.subject | adoptive transfer | en |
dc.subject | *anus cancer/di [Diagnosis] | en |
dc.subject | *anus cancer/dt [Drug Therapy] | en |
dc.subject | *anus cancer/ep [Epidemiology] | en |
dc.subject | *anus cancer/rt [Radiotherapy] | en |
dc.subject | *anus cancer/th [Therapy] | en |
dc.subject | blood toxicity/si [Side Effect] | en |
dc.subject | cancer growth | en |
dc.subject | cancer immunotherapy | en |
dc.subject | cancer incidence | en |
dc.subject | cancer mortality | en |
dc.subject | cancer prognosis | en |
dc.subject | cancer radiotherapy | en |
dc.subject | cancer screening | en |
dc.subject | cancer staging | en |
dc.subject | chemoradiotherapy | en |
dc.subject | colposcopy | en |
dc.subject.mesh | cross infection | - |
dc.subject.mesh | digital rectal examination | - |
dc.subject.mesh | epidemiological data | - |
dc.subject.mesh | hormone action | - |
dc.subject.mesh | immunocompromised patient | - |
dc.subject.mesh | infection | - |
dc.subject.mesh | intensity modulated radiation therapy | - |
dc.subject.mesh | mixed infection | - |
dc.subject.mesh | papillomavirus infection | - |
dc.subject.mesh | pathophysiology | - |
dc.subject.mesh | positron emission tomography-computed tomography | - |
dc.subject.mesh | radiation injury | - |
dc.subject.mesh | salvage therapy | - |
dc.subject.mesh | sexual behavior | - |
dc.subject.mesh | sexually transmitted disease | - |
dc.subject.mesh | smoking habit | - |
dc.subject.mesh | trend study | - |
dc.subject.mesh | uterine cervix cancer | - |
dc.subject.mesh | viral clearance | - |
dc.subject.mesh | virus strain | - |
dc.subject.mesh | atezolizumab | - |
dc.subject.mesh | avelumab | - |
dc.subject.mesh | capecitabine/ct | - |
dc.subject.mesh | capecitabine | - |
dc.subject.mesh | carboplatin/ctcarboplatin | - |
dc.subject.mesh | cetuximab/ct | - |
dc.subject.mesh | cetuximab | - |
dc.subject.mesh | circulating tumor DNA | - |
dc.subject.mesh | cisplatin/ct | - |
dc.subject.mesh | cisplatin | - |
dc.subject.mesh | docetaxel | - |
dc.subject.mesh | durvalumab | - |
dc.subject.mesh | estrogen | - |
dc.subject.mesh | fluorouracil [Adverse Drug Reaction] | - |
dc.subject.mesh | fluorouracil/ct | - |
dc.subject.mesh | fluorouracil | - |
dc.subject.mesh | ipilimumab | - |
dc.subject.mesh | mitomycin [Adverse Drug Reaction] | - |
dc.subject.mesh | nivolumab/ct | - |
dc.subject.mesh | nivolumab | - |
dc.subject.mesh | pembrolizumab/ct | - |
dc.subject.mesh | pembrolizumab | - |
dc.subject.mesh | Wart virus vaccine | - |
dc.subject.mesh | adoptive transfer | - |
dc.subject.mesh | anus cancer | - |
dc.subject.mesh | blood toxicity | - |
dc.subject.mesh | cancer growth | - |
dc.subject.mesh | cancer immunotherapy | - |
dc.subject.mesh | cancer | - |
dc.subject.mesh | cancer radiotherapy | - |
dc.subject.mesh | cancer screening | - |
dc.subject.mesh | cancer staging | - |
dc.subject.mesh | chemoradiotherapy | - |
dc.subject.mesh | colposcopy | - |
dc.title | A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. | en |
dc.type | Review | en |
dc.identifier.affiliation | Oncology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/17474124.2020.1775583 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32458709 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32458709] | en |
dc.identifier.source | 2005380841 | en |
dc.identifier.institution | (Lum, Prenen, Body, Lam, Segelov) Medical Oncology, Monash Medical Centre, Clayton, Australia (Prenen) Oncology Department, University Hospital Antwerp, Antwerp, Belgium (Segelov) School of Clinical Sciences, Monash University, Clayton, Australia | en |
dc.description.address | E. Segelov, Medical Oncology, Monash Medical Centre, Clayton, VIC 3168, Australia. E-mail: eva.segelov@monashhealth.org | en |
dc.subject.keyword | cancer staging | en |
dc.subject.keyword | chemoradiotherapy | en |
dc.subject.keyword | colposcopy | en |
dc.subject.keyword | cross infection | en |
dc.subject.keyword | digital rectal examination | en |
dc.subject.keyword | epidemiological data | en |
dc.subject.keyword | hormone action | en |
dc.subject.keyword | human | en |
dc.subject.keyword | immunocompromised patient | en |
dc.subject.keyword | infection prevention | en |
dc.subject.keyword | intensity modulated radiation therapy | en |
dc.subject.keyword | mixed infection | en |
dc.subject.keyword | nonhuman | en |
dc.subject.keyword | papillomavirus infection | en |
dc.subject.keyword | pathophysiology | en |
dc.subject.keyword | positron emission tomography-computed tomography | en |
dc.subject.keyword | prevalence | en |
dc.subject.keyword | radiation injury | en |
dc.subject.keyword | Review | en |
dc.subject.keyword | risk assessment | en |
dc.subject.keyword | risk factor | en |
dc.subject.keyword | salvage therapy | en |
dc.subject.keyword | sexual behavior | en |
dc.subject.keyword | sexually transmitted disease | en |
dc.subject.keyword | *anus cancer / *diagnosis / *drug therapy / *epidemiology / *radiotherapy / *therapy | en |
dc.subject.keyword | treatment duration | en |
dc.subject.keyword | treatment response | en |
dc.subject.keyword | trend study | en |
dc.subject.keyword | uterine cervix cancer | en |
dc.subject.keyword | viral clearance | en |
dc.subject.keyword | virus strain | en |
dc.subject.keyword | adoptive transfer | en |
dc.subject.keyword | smoking habit | en |
dc.subject.keyword | blood toxicity / side effect | en |
dc.subject.keyword | cancer growth | en |
dc.subject.keyword | cancer immunotherapy | en |
dc.subject.keyword | cancer incidence | en |
dc.subject.keyword | cancer mortality | en |
dc.subject.keyword | cancer prognosis | en |
dc.subject.keyword | cancer radiotherapy | en |
dc.subject.keyword | cancer screening | en |
dc.relation.libraryurl | LibKey Link | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Anal cancer chemoradiation HPV HPV carcinogenesis immunotherapy screening squamous cell carcinoma squamous intraepithelial lesions women | en |
dc.identifier.authoremail | Segelov E.; eva.segelov@monashhealth.org | en |
item.openairetype | Review | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.